Topic:Amphotericin B
Amphotericin B is an antifungal medication used in horses to treat severe fungal infections, particularly those caused by organisms such as Aspergillus and Candida. It works by binding to ergosterol, a key component of fungal cell membranes, creating pores that lead to cell death. Due to its potent antifungal properties, Amphotericin B is often reserved for serious infections that do not respond to other treatments. However, its use in equine medicine is limited by potential side effects, including nephrotoxicity and infusion-related reactions. This page compiles peer-reviewed research studies and scholarly articles that explore the pharmacokinetics, efficacy, safety, and clinical applications of Amphotericin B in equine practice, offering insights into its role in managing fungal infections in horses.
Treatment of pythiosis in equine limbs using intravenous regional perfusion of amphotericin B. To evaluate the effects of intravenous regional limb perfusion (IRLP) administration of amphotericin B in horses to treat pythiosis after surgical excision and thermocautery. Methods: Case series. Methods: Horses (n = 12) with Pythium insidiosum infection of the distal aspect of the thoracic or pelvic limbs. Methods: After surgical excision of granulation tissue and thermocautery, 50 mg amphotericin B was administered by IRLP through a catheter placed in a superficial vein of the affected limb next to the lesion after placing a tourniquet above the injection site. The lesions and locomotor sys...
Successful treatment of cryptococcal pneumonia in a pony mare. A 20-year-old Welsh Mountain Pony (212 kg) mare was initially presented for a chronic cough, fever, weight loss and low grade abdominal pain. She later developed dyspnoea, tachypnoea and exercise intolerance. The presence of multiple masses (up to 17 cm diameter) in the pulmonary parenchyma was established using lateral thoracic radiography and transthoracic ultrasonography. Encapsulated, budding yeasts were observed in smears made from transtracheal washings and needle aspirates of the pulmonary lesions. Cryptococcus gattii (synonym: Cryptococcus neoformans variety gattii; Cryptococcus bacill...
Systemic candidiasis in four foals. Four foals were admitted to the neonatal intensive care unit in the first 2 days of life with problems related to birth hypoxia (neonatal maladjustment syndrome, renal failure, necrotizing enterocolitis) and sepsis. Foals were hospitalized for an extended period (35 to 70 days) and received treatment with several broad spectrum antimicrobial agents. Invasive monitoring and treatment procedures included intravenous catheterization, urinary catheterization, and parenteral nutritional and ventilatory support. In each foal, infections of undetermined cause developed, and systemic candidiasis was d...
Amphotericin B for the treatment of localized subcutaneous phycomycosis in the horse. Amphotericin B was used systemically or locally, or both, in the treatment of localized subcutaneous phycomycosis in horses. In 8 of 10 cases, the results were satisfactory. Intravenous treatment was well tolerated at an average starting daily dosage of 0.38 mg/kg, increasing up to as high as 1.47 mg/kg. It was concluded that the ideal treatment regimen would include early surgical removal of the lesion followed by daily intravenous and topical administration of amphotericin B, with periodic extirpation of small necrotic tracts as necessary.